AI Summary
This article discusses the effectiveness of the Bruton's tyrosine kinase inhibitor tolebrutinib in slowing down disability progression in patients with nonrelapsing secondary progressive multiple sclerosis (nrSPMS). Tolebrutinib is considered a novel agent that has shown benefits in this patient population.
The Bruton’s tyrosine kinase inhibitor tolebrutinib is reportedly the first agent to show benefit in patients with nonrelapsing secondary progressive MS.
Medscape Medical News